
    
      The maximum study duration was up to approximately 58 weeks per participant, consisting of:

        -  up to 2 week screening period

        -  6-month comparative efficacy and safety treatment period

        -  6-month comparative safety extension period

        -  4-week safety follow-up period in a subset of participants

        -  a 3-month administration substudy period starting after completion of the 6-month study
           period for participants willing to in a subset of participants randomized to HOE901-U300
    
  